LANTHANUM CARBONATE (lan-tha'num) Fosrenol Classifications: electrolyte and water balance agent; phosphate binder; Therapeutic: phosphate binder Prototype: Sevelamer hydrochloride Pregnancy Category: C |
250 mg, 500 mg, 750 mg, 1g chewable tablets
Lanthanum is used for the management of hyperphosphatemia in end-stage renal disease; it is a calcium/aluminum-free phosphate binding agent. Has a higher affinity for binding to phosphate than calcium or aluminum. Low systemic absorption minimizes the risk of aluminum intoxication and hypercalcemia. Lanthanum decreases phosphate absorption from the diet. Dietary phosphate bound to lanthanum carbonate is excreted in the feces.
Lowers serum phosphate.
Reduce serum phosphate levels in patients with end-stage renal disease.
Prior hypersensitivity to lanthanum carbonate; pregnancy (category C); children <18 y.
Bowel obstruction, Crohn's disease, acute peptic ulcer, ulcerative colitis; lactation.
Hyperphosphatemia Adult: PO 250500 mg t.i.d. with or immediately after meals; may titrate up every 23 wk in increments of 750 mg/d to achieve acceptable serum phosphate levels (max: 3750 mg/d) |
Assessment & Drug Effects
Patient & Family Education